Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.60 |
| ▸ | RARB | P10826 | 9/20 | 0.60 |
| ▸ | RARG | P13631 | 9/20 | 0.60 |
| ▸ | RARA | P10276 | 4/20 | 0.56 |
| ▸ | RXRG | P48443 | 9/20 | 0.52 |
| ▸ | RXRB | P28702 | 7/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473274 | 1.00 | RXRA (0.60) | RXRARARBRARGRARARXRG | |
| SCHEMBL6472511 | 0.86 | RARG (0.58) | RXRARARBRARGRARARXRG | |
| SCHEMBL6472517 | 0.86 | RARG (0.58) | RXRARARBRARGRARARXRG | |
| SCHEMBL6472449 | 0.85 | RXRA (0.81) | RXRARARBRARGRARARXRG | |
| SCHEMBL6472451 | 0.85 | RXRA (0.81) | RXRARARBRARGRARARXRG | |
| SCHEMBL8027349 | 0.83 | RXRA (0.63) | RXRARARBRARGRARARXRG | |
| SCHEMBL8027346 | 0.83 | RXRA (0.63) | RXRARARBRARGRARARXRG | |
| SCHEMBL6478446 | 0.82 | RARG (0.52) | RXRARARBRARGRARARXRG | |
| SCHEMBL6478447 | 0.82 | RARG (0.52) | RXRARARBRARGRARARXRG | |
| SCHEMBL6049900 | 0.80 | RXRA (0.60) | RXRARARBRARGRARARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | claimed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | claimed |
| EP-0947496-B1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | GALDERMA RES & DEV (FR) | 2002-10-09 | — | — | EP | claimed |
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | RXRA 174/4885RARB 328/4885RARG 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.